Antibiotics are a cornerstone of modern medicine, critical for treating bacterial infections. However, their use during pregnancy requires careful consideration due to potential risks to the developing fetus. A recent study published in JAMA Network Open highlights the risks associated with using trimethoprim-sulfamethoxazole (TMP-SMX) during pregnancy, particularly its link to a higher incidence of infant birth defects compared to other commonly used antibiotics. This study underscores the importance of selecting appropriate treatments for urinary tract infections (UTIs) in pregnant patients.
Understanding UTIs in Pregnancy
Urinary tract infections are among the most common infections during pregnancy, affecting up to 10% of pregnant individuals. These infections are associated with adverse outcomes like preterm birth, low birth weight, and maternal complications such as pyelonephritis and sepsis. Antibiotics, including TMP-SMX, are often prescribed to manage UTIs, especially during the first trimester. However, concerns about congenital malformations linked to certain antibiotics necessitate a closer examination of their safety profiles.
